ASTonix

Company Overview

Snapshot

Founded in June 2026 by Almog Aley-Raz and Prof. Ester Segal, ASTonix operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its rapid diagnostic technology.

Business overview

ASTonix is developing iPRISM, a rapid phenotypic antibiotic susceptibility testing (AST) platform designed for point-of-care diagnosis of urinary tract infections (UTIs). This system aims to provide lab-level susceptibility results within 60–90 minutes during a single patient visit, facilitating evidence-based antibiotic selection and supporting antimicrobial stewardship. The technology utilizes a label-free optical method to monitor bacterial growth dynamics, applying AI classification to generate susceptibility readouts. ASTonix targets clinics, emergency care, hospitals, and high-volume laboratories, with plans to expand beyond UTIs to other infectious diseases like sepsis and fungal infections within the Health Tech & Life Sciences sector, specifically in Medical Devices and Diagnostics Devices.

Company Intelligence Q&A

What is ASTonix's primary product?

ASTonix is developing iPRISM, a rapid phenotypic antibiotic susceptibility testing (AST) platform for urinary tract infections (UTIs).

When was ASTonix founded?

ASTonix was founded in June 2026.

Who are the founders of ASTonix?

The founders of ASTonix are Almog Aley-Raz, who serves as CEO, and Prof. Ester Segal, the Scientific Founder.

What technology does ASTonix's iPRISM platform utilize?

The iPRISM platform uses a label-free optical method, specifically photonic reflectors and spectral shifts, to monitor bacterial growth dynamics, applying AI classification for susceptibility readouts.

Which markets does ASTonix target with its technology?

ASTonix targets clinics, emergency care, hospitals, and high-volume laboratories, with an initial focus on UTIs and potential expansion to other infectious diseases.